Loading…
Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)
In the present study, we investigated the prognostic value of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic non-small cell lung cancer (NSCLC). From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were...
Saved in:
| Published in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2005-10, Vol.50 (1), p.51-58 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c393t-7f2a6efe1ebacf9dde6c459392cfb6ce650e3b2a2ccfbf107167a63a381589f73 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c393t-7f2a6efe1ebacf9dde6c459392cfb6ce650e3b2a2ccfbf107167a63a381589f73 |
| container_end_page | 58 |
| container_issue | 1 |
| container_start_page | 51 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 50 |
| creator | Laack, Eckart Scheffler, Antje Burkholder, Iris Boeters, Ina Andritzky, Birte Schuch, Gunter Görn, Michael Vohwinkel, Gaby Edler, Lutz Fiedler, Walter Hossfeld, Dieter Kurt |
| description | In the present study, we investigated the prognostic value of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were analysed in 194 patients of a randomized phase III trial with enzyme-linked immunoassays.
Patients with a VEGF serum level higher than the median serum level (10,995
pg/ml) had a significantly shorter overall survival than those with a lower serum level (
P
=
0.04). The MMP-9 serum level did not correlate with survival. In a multivariate Cox regression analysis, only the pretreatment serum level of VEGF, the Karnofsky performance status, and the presence of bone metastases were identified as independent prognostic factors.
The pretreatment VEGF serum level was identified as independent prognostic factor in this study and may help to assess individual risk and treatment profiles in patients with metastatic NSCLC. |
| doi_str_mv | 10.1016/j.lungcan.2005.05.011 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68591193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500205002527</els_id><sourcerecordid>68591193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-7f2a6efe1ebacf9dde6c459392cfb6ce650e3b2a2ccfbf107167a63a381589f73</originalsourceid><addsrcrecordid>eNqFkV1rFDEUhgdR7Fr9CUpulO7FrPkwmcmVyNJWYasFP25DNnPSZslktklm2_4k_6UZdqCXwiEh4Tnv-Xir6i3BK4KJ-Lhb-THcGB1WFGO-moKQZ9WCtA2tW8bo82pROFlzjOlJ9SqlHcakIVi-rE4Il5JKLhfV3-sIOYLOPYSMDjqZ0euIIHRDvgXvtEc3cbjPt8hqk4eIzv6cX14skQ4d6nWO7gH1kLX3wz4OGVzQCWqJzq6urmu5RAni2CMPB_AJuYD2OrtSKKF7VySnzJTLl0FhCHXqiw4yUI5pNlSGM1Aqfv-53qyXr6sXVvsEb-b7tPp9cf5r_bXe_Lj8tv6yqQ2TLNeNpVqABQJbbazsOhDmE5dMUmO3woDgGNiWamrK2xLcENFowTRrCW-lbdhp9eGoWwa6GyFl1bs0NaUDDGNSouWSEMkKyI-giUNKEazaR9fr-KgIVpNHaqdmj9TkkZqCkJL3bi4wbnvonrJmUwrwfgaKHdrbWPbg0hPXEMqFmBr4fOTKcuHgIKpkynYNdC6Cyaob3H9a-Qf6PrU8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68591193</pqid></control><display><type>article</type><title>Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)</title><source>Elsevier</source><creator>Laack, Eckart ; Scheffler, Antje ; Burkholder, Iris ; Boeters, Ina ; Andritzky, Birte ; Schuch, Gunter ; Görn, Michael ; Vohwinkel, Gaby ; Edler, Lutz ; Fiedler, Walter ; Hossfeld, Dieter Kurt</creator><creatorcontrib>Laack, Eckart ; Scheffler, Antje ; Burkholder, Iris ; Boeters, Ina ; Andritzky, Birte ; Schuch, Gunter ; Görn, Michael ; Vohwinkel, Gaby ; Edler, Lutz ; Fiedler, Walter ; Hossfeld, Dieter Kurt</creatorcontrib><description>In the present study, we investigated the prognostic value of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were analysed in 194 patients of a randomized phase III trial with enzyme-linked immunoassays.
Patients with a VEGF serum level higher than the median serum level (10,995
pg/ml) had a significantly shorter overall survival than those with a lower serum level (
P
=
0.04). The MMP-9 serum level did not correlate with survival. In a multivariate Cox regression analysis, only the pretreatment serum level of VEGF, the Karnofsky performance status, and the presence of bone metastases were identified as independent prognostic factors.
The pretreatment VEGF serum level was identified as independent prognostic factor in this study and may help to assess individual risk and treatment profiles in patients with metastatic NSCLC.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/j.lungcan.2005.05.011</identifier><identifier>PMID: 15992959</identifier><identifier>CODEN: LUCAE5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adult ; Aged ; Angiogenic factors ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - pathology ; Enzyme-Linked Immunosorbent Assay ; Female ; Follow-Up Studies ; Humans ; Lung Neoplasms - pathology ; Male ; Matrix Metalloproteinase 9 - blood ; Medical sciences ; Middle Aged ; MMP-9 ; NSCLC ; Pneumology ; Prognosis ; Prognostic factors ; Survival Analysis ; Tumors of the respiratory system and mediastinum ; Vascular Endothelial Growth Factor A - blood ; VEGF</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2005-10, Vol.50 (1), p.51-58</ispartof><rights>2005 Elsevier Ireland Ltd</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-7f2a6efe1ebacf9dde6c459392cfb6ce650e3b2a2ccfbf107167a63a381589f73</citedby><cites>FETCH-LOGICAL-c393t-7f2a6efe1ebacf9dde6c459392cfb6ce650e3b2a2ccfbf107167a63a381589f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17125663$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15992959$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Laack, Eckart</creatorcontrib><creatorcontrib>Scheffler, Antje</creatorcontrib><creatorcontrib>Burkholder, Iris</creatorcontrib><creatorcontrib>Boeters, Ina</creatorcontrib><creatorcontrib>Andritzky, Birte</creatorcontrib><creatorcontrib>Schuch, Gunter</creatorcontrib><creatorcontrib>Görn, Michael</creatorcontrib><creatorcontrib>Vohwinkel, Gaby</creatorcontrib><creatorcontrib>Edler, Lutz</creatorcontrib><creatorcontrib>Fiedler, Walter</creatorcontrib><creatorcontrib>Hossfeld, Dieter Kurt</creatorcontrib><title>Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>In the present study, we investigated the prognostic value of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were analysed in 194 patients of a randomized phase III trial with enzyme-linked immunoassays.
Patients with a VEGF serum level higher than the median serum level (10,995
pg/ml) had a significantly shorter overall survival than those with a lower serum level (
P
=
0.04). The MMP-9 serum level did not correlate with survival. In a multivariate Cox regression analysis, only the pretreatment serum level of VEGF, the Karnofsky performance status, and the presence of bone metastases were identified as independent prognostic factors.
The pretreatment VEGF serum level was identified as independent prognostic factor in this study and may help to assess individual risk and treatment profiles in patients with metastatic NSCLC.</description><subject>Adult</subject><subject>Aged</subject><subject>Angiogenic factors</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Matrix Metalloproteinase 9 - blood</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>MMP-9</subject><subject>NSCLC</subject><subject>Pneumology</subject><subject>Prognosis</subject><subject>Prognostic factors</subject><subject>Survival Analysis</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><subject>VEGF</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqFkV1rFDEUhgdR7Fr9CUpulO7FrPkwmcmVyNJWYasFP25DNnPSZslktklm2_4k_6UZdqCXwiEh4Tnv-Xir6i3BK4KJ-Lhb-THcGB1WFGO-moKQZ9WCtA2tW8bo82pROFlzjOlJ9SqlHcakIVi-rE4Il5JKLhfV3-sIOYLOPYSMDjqZ0euIIHRDvgXvtEc3cbjPt8hqk4eIzv6cX14skQ4d6nWO7gH1kLX3wz4OGVzQCWqJzq6urmu5RAni2CMPB_AJuYD2OrtSKKF7VySnzJTLl0FhCHXqiw4yUI5pNlSGM1Aqfv-53qyXr6sXVvsEb-b7tPp9cf5r_bXe_Lj8tv6yqQ2TLNeNpVqABQJbbazsOhDmE5dMUmO3woDgGNiWamrK2xLcENFowTRrCW-lbdhp9eGoWwa6GyFl1bs0NaUDDGNSouWSEMkKyI-giUNKEazaR9fr-KgIVpNHaqdmj9TkkZqCkJL3bi4wbnvonrJmUwrwfgaKHdrbWPbg0hPXEMqFmBr4fOTKcuHgIKpkynYNdC6Cyaob3H9a-Qf6PrU8</recordid><startdate>20051001</startdate><enddate>20051001</enddate><creator>Laack, Eckart</creator><creator>Scheffler, Antje</creator><creator>Burkholder, Iris</creator><creator>Boeters, Ina</creator><creator>Andritzky, Birte</creator><creator>Schuch, Gunter</creator><creator>Görn, Michael</creator><creator>Vohwinkel, Gaby</creator><creator>Edler, Lutz</creator><creator>Fiedler, Walter</creator><creator>Hossfeld, Dieter Kurt</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051001</creationdate><title>Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)</title><author>Laack, Eckart ; Scheffler, Antje ; Burkholder, Iris ; Boeters, Ina ; Andritzky, Birte ; Schuch, Gunter ; Görn, Michael ; Vohwinkel, Gaby ; Edler, Lutz ; Fiedler, Walter ; Hossfeld, Dieter Kurt</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-7f2a6efe1ebacf9dde6c459392cfb6ce650e3b2a2ccfbf107167a63a381589f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Angiogenic factors</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Matrix Metalloproteinase 9 - blood</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>MMP-9</topic><topic>NSCLC</topic><topic>Pneumology</topic><topic>Prognosis</topic><topic>Prognostic factors</topic><topic>Survival Analysis</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><topic>VEGF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Laack, Eckart</creatorcontrib><creatorcontrib>Scheffler, Antje</creatorcontrib><creatorcontrib>Burkholder, Iris</creatorcontrib><creatorcontrib>Boeters, Ina</creatorcontrib><creatorcontrib>Andritzky, Birte</creatorcontrib><creatorcontrib>Schuch, Gunter</creatorcontrib><creatorcontrib>Görn, Michael</creatorcontrib><creatorcontrib>Vohwinkel, Gaby</creatorcontrib><creatorcontrib>Edler, Lutz</creatorcontrib><creatorcontrib>Fiedler, Walter</creatorcontrib><creatorcontrib>Hossfeld, Dieter Kurt</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Laack, Eckart</au><au>Scheffler, Antje</au><au>Burkholder, Iris</au><au>Boeters, Ina</au><au>Andritzky, Birte</au><au>Schuch, Gunter</au><au>Görn, Michael</au><au>Vohwinkel, Gaby</au><au>Edler, Lutz</au><au>Fiedler, Walter</au><au>Hossfeld, Dieter Kurt</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2005-10-01</date><risdate>2005</risdate><volume>50</volume><issue>1</issue><spage>51</spage><epage>58</epage><pages>51-58</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><coden>LUCAE5</coden><abstract>In the present study, we investigated the prognostic value of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were analysed in 194 patients of a randomized phase III trial with enzyme-linked immunoassays.
Patients with a VEGF serum level higher than the median serum level (10,995
pg/ml) had a significantly shorter overall survival than those with a lower serum level (
P
=
0.04). The MMP-9 serum level did not correlate with survival. In a multivariate Cox regression analysis, only the pretreatment serum level of VEGF, the Karnofsky performance status, and the presence of bone metastases were identified as independent prognostic factors.
The pretreatment VEGF serum level was identified as independent prognostic factor in this study and may help to assess individual risk and treatment profiles in patients with metastatic NSCLC.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>15992959</pmid><doi>10.1016/j.lungcan.2005.05.011</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2005-10, Vol.50 (1), p.51-58 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68591193 |
| source | Elsevier |
| subjects | Adult Aged Angiogenic factors Biological and medical sciences Carcinoma, Non-Small-Cell Lung - pathology Enzyme-Linked Immunosorbent Assay Female Follow-Up Studies Humans Lung Neoplasms - pathology Male Matrix Metalloproteinase 9 - blood Medical sciences Middle Aged MMP-9 NSCLC Pneumology Prognosis Prognostic factors Survival Analysis Tumors of the respiratory system and mediastinum Vascular Endothelial Growth Factor A - blood VEGF |
| title | Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC) |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T11%3A36%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20vascular%20endothelial%20growth%20factor%20(VEGF)%20and%20matrix%20metalloproteinase-9%20(MMP-9)%20serum%20levels%20in%20patients%20with%20metastatic%20non-small%20cell%20lung%20cancer%20(NSCLC)&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Laack,%20Eckart&rft.date=2005-10-01&rft.volume=50&rft.issue=1&rft.spage=51&rft.epage=58&rft.pages=51-58&rft.issn=0169-5002&rft.eissn=1872-8332&rft.coden=LUCAE5&rft_id=info:doi/10.1016/j.lungcan.2005.05.011&rft_dat=%3Cproquest_cross%3E68591193%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-7f2a6efe1ebacf9dde6c459392cfb6ce650e3b2a2ccfbf107167a63a381589f73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68591193&rft_id=info:pmid/15992959&rfr_iscdi=true |